News

In 2022, the Rusatom Healthcare plans to launch the project “Development of a Modern Pharmaceutical Manufacturing of Isotopic Medical Products at the Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) Facilities in Obninsk of Kaluga Oblast”. The investment volume is planned not less than nine billion rubles.

The project will be implemented in compliance with the GMP standards. With opening of the plant, the Rosatom State Corporation will change the Russian position on the global market of nuclear medicine. Hosted by the Karpov NIFKhl, the plant will become the world's leading enterprise, manufacturing a wide range of radiopharmaceutical agents.

The positive review from the RF State Expert Evaluation Department opens the way to start of the construction in 2022.

Implementation of this project is a well-timed response of Rosatom to the growing demand of Russian and global health care in radiopharmaceuticals, which are used in the course of  high-tech medical care for patients with oncological, rheumatological, endocrinological, and cardiological diseases.

According to the World Health Organization information for 2020, the number of diagnosed oncological diseases keeps growing; today it is 19.3 million cases globally, and 591 thousand cases in Russia per year. Diagnostics with radiopharmaceuticals helps to expose diseases for dozens of millions of people throughout the world and start their treatment timely; that treatment also involves application of isotopic products. In the long run, treatment procedures with usage of radiopharmaceuticals will help hundreds of thousand people per year.

Rosatom ranks in the Top 5 of the world’s leading suppliers of raw isotopic products; it is the key supplier of isotopic medical products on the Russian market, delivering radiopharmaceuticals to more than 180 medical facilities of the Russian Federation.

Based on the Rusatom Healthcare Press Service.